このエントリーをはてなブックマークに追加
ID 58764
著者
Higo, Hisao Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Miyahara, Nobuaki Okayama University Hospital Kaken ID researchmap
Taniguchi, Akihiko Okayama University Hospital Kaken ID
Senoo, Satoru Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Itano, Junko Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Watanabe, Hiromi Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Oda, Naohiro Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kayatani, Hiroe National Hospital Organization Okayama Medical Center
Ichikawa, Hirohisa KKR Takamatsu Hospita
Shibayama, Takuo National Hospital Organization Okayama Medical Center
Kajimoto, Kazuhiro Kobe Red Cross Hospital
Tanimoto, Yasushi National Hospital Organization Minami-Okayama Medical Center Kaken ID researchmap
Kanehiro, Arihiko Okayama Rosai Hospital
Maeda, Yoshinobu Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Kaken ID researchmap
Kiura, Katsuyuki Okayama University Hospital Kaken ID researchmap
OKAYAMA respiratory disease study group (ORDSG)
抄録
Background
Pirfenidone suppresses the decline of forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF). However, IPF progresses in some patients despite treatment. We analyzed patients with meaningful FVC declines during pirfenidone treatment and explored the factors predictive of disease progression after FVC decline.
Methods
This study was a retrospective, multicenter, observational study conducted by the Okayama Respiratory Disease Study Group. We defined initial decline in %FVC as 5% or greater per 6-month period during pirfenidone treatment. IPF patients who were treated with pirfenidone and experienced an initial decline from December 2008 to September 2017 were enrolled.
Results
We analyzed 21 patients with IPF. After the initial decline, 4 (19.0%) patients showed improvement in disease, 11 (52.4%) showed stable disease, and 6 (28.6%) showed progressive disease. There was no significant correlation between %FVC reduction on initial decline and subsequent %FVC change (p = 0.475). Deterioration of high-resolution computed tomography (HRCT) findings on initial decline was observed significantly more often in the progressive versus improved/stable disease groups (100% vs 20.0%, p = 0.009).
Conclusions
We revealed that deterioration of HRCT findings may predict disease progression after the initial decline in %FVC in IPF patients treated with pirfenidone.
キーワード
Idiopathic pulmonary fibrosis
High-resolution computed tomography
Pirfenidone
Forced vital capacity
備考
This fulltext is available in Feb. 2021.
発行日
2020-02-23
出版物タイトル
Respiratory Investigation
58巻
3号
出版者
Elsevier
開始ページ
185
終了ページ
189
ISSN
22125345
NCID
AA12579673
資料タイプ
学術雑誌論文
言語
English
論文のバージョン
author
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.1016/j.resinv.2019.12.007